Study on radiation and hormone therapy after prostate surgery
Part of Cancer, Kidney & urinary clinical trials.
This study looks at using radiation therapy and hormone therapy together after prostate cancer surgery. It aims to understand how these treatments work and who may benefit most.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with prostate cancer that has not spread to other parts of the body.
- You have had surgery to remove your prostate.
- Your PSA level after surgery is less than 0.4 ng/mL.
- You have not had hormone therapy before or had your testicles removed.
- You have not had radiation therapy to the pelvic area before.
- You are already part of the RADICALS main study and agreed to take part in this additional research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a combination of short-term hormone therapy (relugolix) and focused radiation (SBRT) can treat a certain type of prostate cancer that is considered favorable but has a higher genetic risk. It aims to find a less intense treatment that still works well.
This Phase 3 trial compares two treatment approaches: stereotactic radiation therapy by itself versus the same radiation plus hormone therapy (ADT). It aims to see which plan works better for men with higher-risk prostate cancer without spread to lymph nodes or distant sites.
This trial compares two ways of giving hormone therapy (apalutamide) along with radiation after prostate removal surgery. It aims to see which approach helps maintain quality of life while controlling cancer.
This trial studies giving hormone treatment and radiation before prostate surgery to treat high-risk, locally advanced prostate cancer. It aims to improve cancer control by shrinking or controlling the tumor before removing it.
This study tests whether adding a type of high-precision radiation (MDRT) to standard hormone therapy works better for men with prostate cancer that has spread to just a few places. It is for patients who are newly diagnosed and on long-term hormone therapy.
This trial studies whether giving a shorter-course radiation plan after prostate surgery, along with hormone shots (LHRH), can improve outcomes for people with higher-risk prostate cancer. You may be eligible if your PSA (a blood marker) is either still low but high-risk by pathology, or it has started to rise again after surgery.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.